ReviewTherapeutic advances in musculoskeletal disease2020
Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations.
Review in Therapeutic advances in musculoskeletal disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 55 citations in OpenAlex.
- Two Diagnostic Challenges in Hepatitis B Serology: Low HBsAg S/CO Values and Isolated Anti-HBc Positivity.Pathogens (Basel, Switzerland) · 2026Article
- The BTLA/HVEM axis as a key regulator for stratified functional cure in chronic hepatitis B.Frontiers in immunology · 2026Review
- HCV Reactivation Risk in Patients Undergoing Treatment for Inflammatory Arthritis and Connective Tissue Diseases.Mediterranean journal of rheumatology · 2025Article
- Microscopic polyangiitis complicated with pulmonary hepatitis B virus infection: A case report and literature review.Infectious medicine · 2025Article
- Coexistence of VEXAS Syndrome and Chronic Hepatitis B Virus Infection: a Case Report and Literature Review.Clinical reviews in allergy & immunology · 2025Review
- Bridging the rheumatology resource gap in Africa.Clinical rheumatology · 2025Article
- The type of infections and the use of antibiotics among patients with rheumatoid arthritis: A review.Journal of family medicine and primary care · 2025Review
- Current perspective on infections and mitigation strategies in primary systemic vasculitis.Current rheumatology reports · 2024Review
- Upadacitinib-Induced Hepatitis B Reactivation Leading to Liver Transplant.ACG case reports journal · 2024Article
- Interleukin-1 Blockers: A Paradigm Shift in the Treatment of Recurrent Pericarditis.Life (Basel, Switzerland) · 2024Review
- Article
- Improving Hepatitis B Screening Prior to Rituximab: A Quality Improvement Project.Children (Basel, Switzerland) · 2023Article
- Risk of Hepatitis B Virus (HBV) Reactivation in HBsAg-Negative, Anti-HBc-Negative Patients Receiving Rituximab for Autoimmune Diseases in HBV Endemic Areas.Gut and liver · 2023Article
- The association of uveitis with hepatitis B and hepatitis C viruses: a large-scale population-based study.Eye (London, England) · 2023Article
- Effect of an Electronic Alert System on Hepatitis B Virus Reactivation in Patients Receiving Immunosuppressive Drug Therapy.Journal of clinical medicine · 2022Article
- Long-term safety of rituximab in rheumatic patients with previously resolved hepatitis B virus infection.Internal and emergency medicine · 2022Article
- Viral neuromyopathy associated with acute hepatitis B infection.BMJ case reports · 2022Article
- Effectiveness and safety of low-dose interferon alpha-2a treatment in Behçet's Syndrome with refractory vascular or neurological involvement: a case series.Therapeutic advances in chronic disease · 2022Article
- Hepatitis B Screening Before Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug Therapy: Many Roads to Improvement.The Journal of rheumatology · 2022Article
- Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment.Digestive diseases and sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In patients with rheumatic diseases undergoing immunosuppressive treatment, hepatitis B virus reactivation (HBVr) has been long recognized as a major treatment-related adverse event with substantial morbidity and mortality. Because HBVr is easily preventable with appropriate screening and monitoring strategies, and, when indicated, prophylactic antiviral treatment, awareness of this complication is of the utmost importance, especially in the era of biologic treatments. As a condition, it continues to be topical, in view of the emergence of novel classes of immunosuppressive drugs (i.e. Janus kinase inhibitors) acquiring licenses for a variety of rheumatic diseases. The class-specific risk of these agents for HBVr has not yet been determined. Moreover, ambiguity still exists for the management of patients planned to be treated with traditional agents, such as cyclophosphamide and glucocorticoids, particularly in the setting of resolved HBV infection. Clinicians in the field of rheumatic diseases should be tailoring their practice according to the host's profile and treatment-specific risk for HBVr. In this review, the authors attempt to critically review the existing literature and provide practical advice on these issues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.